Abstract
Background. Rational development of drugs to prevent human immunodeficiency virus (HIV) transmission benefits from an understanding HIV distribution in the female genital tract after intercourse. This study describes HIV distribution using surrogates of cell-free and cell-associated HIV and semen.Methods. Apheresis-derived, autologous, lymphocyte-rich cells radiolabeled with 3.7-MBq (100-μCi) indium 111 ( 111In)-oxine (cell-associated HIV surrogate) and 18.5-MBq (500-μCi) technetium 99m ( 99mTc)-sulfur colloid (HIV-sized 100-nm particle, cell-free HIV surrogate) were resuspended in 3 mL of hydroxyethylcellulose gel (semen simulant) with gadoteridol and dosed via artificial phallus after simulated intercourse. Postdosing dual-isotope single photon emission computed tomography with computed tomography (SPECT/CT) and magnetic resonance (MR) images were acquired to determine the surrogates' distribution. Seven hours after dosing, vaginal biopsy and luminal samples were collected at discrete locations in 8 subjects.Results.SPECT/CT and MR analysis showed HIV and semen surrogate distribution with highest signal intensity in the vaginal pericervical area, without detectable signal in the uterus. One-third of the administered dose was retained in the female genital tract after 4 hours. Cell-free and cell-associated surrogate distribution coincided.Conclusions.We demonstrate the feasibility of dual-isotope SPECT/CT and MR imaging to determine the distribution of HIV and semen surrogates after simulated intercourse without disrupting vaginal contents. Surrogate distribution suggests topical microbicides do not need to reach the uterus for efficacy.
Original language | English |
---|---|
Pages (from-to) | 725-732 |
Number of pages | 8 |
Journal | Journal of Infectious Diseases |
Volume | 205 |
Issue number | 5 |
DOIs | |
Publication status | Published - Mar 1 2012 |
Bibliographical note
Funding Information:Financial support. This work was supported by funding from the US Agency for International Development (contract GPOA 0005004100) through the International Partnership for Microbicides. Potential conflicts of interest. All authors: No reported conflicts.
Funding
Financial support. This work was supported by funding from the US Agency for International Development (contract GPOA 0005004100) through the International Partnership for Microbicides. Potential conflicts of interest. All authors: No reported conflicts.
Funders | Funder number |
---|---|
National Institute of General Medical Sciences | T32GM066691 |
United States Agency for International Development | GPOA 0005004100 |
ASJC Scopus Subject Areas
- Immunology and Allergy
- Infectious Diseases